Subject(s)
Hemophilia A , Medicine , Sex Chromosome Disorders , Factor IX , Factor VIII , Hemophilia A/drug therapy , HumansABSTRACT
BACKGROUND: In spite of recent major advances in the understanding and treatment of inhibitor development in patients with haemophilia, multidisciplinary management of many of these patients remains suboptimal and highly heterogenous across Europe. METHODS: Following a series of multidisciplinary meetings and a review of the literature, the European haemophilia community of health professionals and patients jointly defined practical optimum standards for ensuring and harmonizing treatment and care for patients with an inhibitor. RESULTS: Ten complementary principles for the management of inhibitors in haemophilia have been developed, emphasizing the importance and benefits of a centralized, multidisciplinary, expert and holistic approach. CONCLUSIONS: This document will serve as a benchmark to improve the multidisciplinary and practical management of patients with inhibitor. Implementation and adherence to each of these principles should have a major positive impact on the management and outcomes of patients developing an inhibitor.
Subject(s)
Factor IX/metabolism , Factor VIII/metabolism , Hemophilia A/metabolism , Europe , HumansABSTRACT
INTRODUCTION: This report summarizes recommendations relating to haemophilia therapy arising from discussions among experts from 36 European countries during the 'Kreuth IV' meeting in May 2016. AIM: The objective of the meeting was for experts in the field of haemophilia from across Europe to draft resolutions regarding current issues relating to the treatment of haemophilia. RESULTS: Hospitals providing clinical care for people with haemophilia and related disorders are strongly recommended to seek formal designation as either European Haemophilia Treatment Centres (EHTC) or European Haemophilia Comprehensive Care Centres (EHCCC). There should be agreed national protocols or guidelines on management of the ageing patient with haemophilia. The minimum consumption of factor VIII and IX concentrate in any country should be 4 IU and 0.5 IU per capita of general population respectively. Treatment for hepatitis C with direct-acting antiviral agents should be provided to all people with haemophilia on a priority basis. Genotype analysis should be offered to all patients with severe haemophilia. Genetic counselling, when given, should encompass the recommendation that genetic relatives of the affected person be advised to seek genetic counselling. People with inhibitors should have access to bypassing agents, immune tolerance and elective surgery. National or regional tenders for factor concentrates are encouraged. Outcome data including health related quality of life should be collected. Treatment with extended half-life factors should be individualized and protection against bleeding should be improved by increasing trough levels. Steps should be taken to understand and minimize the risk of inhibitor development. CONCLUSION: It is hoped that these recommendations will help to foster equity of haemophilia care throughout Europe.
Subject(s)
Blood Coagulation Factors/therapeutic use , Consensus , Hemophilia A/drug therapy , Europe , HumansABSTRACT
A questionnaire was circulated in 2012 to national haemophilia patient organizations in Europe affiliated to the European Haemophilia Consortium (EHC) and the World Federation of Hemophilia (WFH) to seek information about the organization of haemophilia care and treatment available at a national level. The 35 responses received highlighted major differences in the availability of treatment and care. There was a wide range in factor VIII consumption with usage ranging from 0.20 IU per capita in Armenia to 8.56 IU per capita in Sweden (median: IU per capita). The decrease in health budgets in many countries was not matched by decreases in use of FVIII per capita. In the 19 countries that responded to the previous survey, there was a significant improvement in access to prophylaxis and home treatment.
Subject(s)
Health Care Surveys , Hemophilia A/epidemiology , Hemophilia A/therapy , Patient Care/statistics & numerical data , Decision Making , Europe/epidemiology , Gross Domestic Product , Health Services Accessibility/statistics & numerical data , Hemophilia A/immunology , Hemophilia A/prevention & control , Home Care Services/statistics & numerical data , Humans , Immune Tolerance/immunology , Registries/statistics & numerical data , Specialization/statistics & numerical data , Surveys and Questionnaires , von Willebrand Diseases/therapyABSTRACT
The aim of this study was to determine the clinical conditions of patients with haemophilia within Europe as recommended by the European Commission. In this multicentre, cross-sectional, ambispective study, conducted within 21 European countries patients' clinical data were collected, amongst others haemophilia type, severity, treatment pattern, use of factor products, bleeding, orthopaedic joint scores and infections. A total of 1400 patients, 84.3% with haemophilia A and 15.7% with haemophilia B were enrolled by 42 centres between 2004 and 2006. Thereof, 417 were children (30.0%) and 983 were adults (70.0%). About 70% of patients had severe factor deficiency (<1%). More than half of the adults were carriers of chronic infections (12.6% HIV, 55.8% HCV), compared to only 3.8% children (no HIV, 2.9% HCV). Patients were grouped according to per capita amount of clotting factor used in patients' region of residence in 2005: region 1: >5 IU; region 2: 2-5 IU; region 3: <2 IU. Paediatric and adult patients in region 3 had median numbers of three and eight joint bleeds, respectively, with worse joint scores compared to region 1 with zero and one bleed. Prophylactic therapy was used in only 31.3% children and 8.9% adults with severe haemophilia in region 3 compared to 93.7% and 54.1%, respectively, in region 1. Statistical analysis revealed that residence in areas with low factor consumption/availability is the most prominent risk factor for joint disease. Access of European patients with haemophilia to optimal care with safe factor VIII concentrates is limited and depends on the region of residence.
Subject(s)
Hemophilia A/therapy , Hemophilia B/therapy , Adolescent , Adult , Aged , Aged, 80 and over , Blood Coagulation Factors/administration & dosage , Blood Coagulation Factors/economics , Child , Child, Preschool , Cross-Sectional Studies , Europe/epidemiology , Health Services Accessibility , Hemarthrosis/etiology , Hemophilia A/complications , Hemophilia A/economics , Hemophilia A/epidemiology , Hemophilia B/complications , Hemophilia B/economics , Hemophilia B/epidemiology , Humans , Male , Middle Aged , Prospective Studies , Quality of Life , Retrospective Studies , Risk Factors , Young AdultSubject(s)
Coagulants/therapeutic use , Factor VIII/therapeutic use , Hemophilia A/drug therapy , Animals , Animals, Genetically Modified , Cattle , Coagulants/adverse effects , Coagulants/history , Factor VIII/adverse effects , Factor VIII/history , Factor VIII/immunology , History, 20th Century , Humans , Recombinant Proteins/therapeutic use , SwineABSTRACT
In 2009, a questionnaire was circulated to 19 national haemophilia patient organizations in Europe affiliated to the European Haemophilia Consortium (EHC) and the World Federation of Hemophilia (WFH) to seek information about the organization of haemophilia care and treatment available at a national level. The responses received highlighted differences in the level of care despite the recent promulgation of consensus guidelines designed to standardize the care of haemophilia throughout the continent of Europe. There was a wide range in factor VIII consumption with usage ranging from 0.38 IU per capita in Romania to 8.7 IU per capita in Sweden (median: 3.6 IU per capita). Despite the specific inclusion of coagulation factor concentrate in the WHO list of essential medications, cryoprecipitate is still used in some eastern European countries.
Subject(s)
Delivery of Health Care/organization & administration , Factor VIII/therapeutic use , Hemophilia A/drug therapy , Europe , Health Services Accessibility , Home Care Services/organization & administration , Humans , Surveys and QuestionnairesABSTRACT
The workshop looked at seven scenarios based on fictional and real-life cases of difficult-to-treat patients with haemophilia A or haemophilia B and inhibitors with the aim of sharing clinical opinion and experience from around the world. Delegate opinions on the best treatment option for each scenario are described together with actual treatment given in real-life cases and its outcome.
Subject(s)
Blood Coagulation Factor Inhibitors , Blood Coagulation Factors/therapeutic use , Hemophilia A/drug therapy , Hemophilia B/drug therapy , Hemorrhage/prevention & control , Adolescent , Adult , Child , Child, Preschool , Factor VIIa/therapeutic use , Humans , Joint Diseases/drug therapy , Male , Recombinant Proteins/therapeutic use , Young AdultABSTRACT
Patients with haemophilia complicated by inhibitors have a significant burden of joint disease, which is associated with a negative impact on their quality of life. Successful elective orthopaedic surgery can result in decreased bleed frequency into a new joint, less time spent in hospital, increased mobility and improved well being. This paper describes a new protocol for use of recombinant activated factor VII (rFVIIa) in elective orthopaedic surgery, based on a review of published data as well as the personal experience of a group of expert physicians. The protocol offers guidance on the planning of the surgery and preoperative testing as well as the bolus schedule for rFVIIa and advice on the concomitant use of antifibrinolytic agents and fibrin sealants. A total of 10 operations involving 13 procedures in eight patients in five comprehensive care centres have been undertaken until now using the protocol, which employs an initial bolus dose of rFVIIa in the range of 120-180 microg kg(-1) to cover surgery. The clinical experience reported here encompasses all cases of elective orthopaedic surgery using rFVIIa as initial treatment carried out in the UK and Republic of Ireland over the last 2 years. In all cases, there was good control of haemostasis during surgery and the final outcome was rated as 'excellent' or 'extremely satisfactory' by the reporting clinicians. Although the initial cost of product to cover surgery such as arthroplasty is high, it needs to be borne in mind that this may be offset in subsequent years by savings resulting from avoidance of bleeding episodes in the affected joint.
Subject(s)
Consensus Development Conferences as Topic , Factor VIIa/therapeutic use , Hemophilia A/drug therapy , Joint Diseases/surgery , Postoperative Hemorrhage/prevention & control , Recombinant Proteins/therapeutic use , Adolescent , Adult , Aged , Blood Loss, Surgical/prevention & control , Child , Child, Preschool , Clinical Protocols , Elective Surgical Procedures , Hemophilia A/complications , Humans , Middle Aged , Orthopedic Procedures/adverse effects , Treatment Outcome , Young AdultABSTRACT
We describe a young boy with severe haemophilia B who developed inhibitory antibodies and an anaphylactoid reaction to factor IX. Immune tolerance was achieved by desensitisation with escalating doses of factor IX followed by the Malmö regimen.
Subject(s)
Anaphylaxis/immunology , Factor IX/adverse effects , Hemophilia B/drug therapy , Immune Tolerance , Antibodies/immunology , Child, Preschool , Drug Administration Schedule , Hemophilia B/immunology , Humans , Male , Treatment OutcomeABSTRACT
To establish the pharmacokinetic profile of activated recombinant coagulation factor VII (rFVIIa; NovoSeven in children with haemophilia A, and to compare it with the pharmacokinetic profile in adults with haemophilia A. Twelve children (2-12 years) received one single dose of rFVIIa 90 and 180 micrograms kg(-1) in randomized order separated by a washout period of 48 h to 1 month. Six adults (18-55 years) received a single dose of rFVIIa 90 micrograms kg(-1). The pharmacokinetic analyses were based on a non-compartmental method. In children, the plasma level of FVII increased proportionally with the dose. The total body clearance normalized for body weight was significantly faster in children than in adults (FVII:C, 58 vs. 39 mL kg(-1) h(-1) and FVIIa, 78 vs. 53 mL kg(-1) h(-1), P < 0.05). A trend towards a larger volume of distribution at steady-state in children than in adults was observed (P > 0.05). Dose proportionality was established for plasma concentrations of FVII in children with haemophilia A at the dose levels investigated (90 and 180 micrograms kg(-1) rFVIIa). Following administration of rFVIIa 90 micrograms kg(-1), significantly faster clearance was observed in children compared with adults, suggesting that higher doses of rFVIIa may be needed to achieve the same plasma levels as in adults.
Subject(s)
Factor VII/pharmacokinetics , Hemophilia A/metabolism , Recombinant Proteins/pharmacokinetics , Child , Child, Preschool , Factor VII/analysis , Factor VIIa/analysis , Half-Life , Humans , Injections, Intravenous , Plasma/chemistryABSTRACT
BACKGROUND: Previous studies of the development of inhibitors and their impact on mortality have been small. OBJECTIVES: To examine the development of inhibitors in people with hemophilia in the UK and their effect on subsequent mortality. PATIENTS: 6078 males with hemophilia A and 1172 males with hemophilia B registered in the UK Haemophilia Centre Doctors' Organisation database, 1977-98. RESULTS: In severe hemophilia A inhibitors developed at rates of 34.4, 5.2 and 3.8 per 1000 years at ages <5, 5-14 and 15+years; cumulative risks at ages 5 and 75 were 16% and 36%. In hemophilia A the rate of inhibitor development decreased during 1977-90, but increased during the 1990s. In severe hemophilia B inhibitors developed at rates of 13.3 and 0.2 per 1000 years at ages <5 and 5+ and cumulative risks at ages 5 and 75 were 6% and 8%. With HIV, inhibitor development did not increase mortality. In severe hemophilia without HIV, inhibitor development doubled mortality during 1977-92, but during 1993-99 mortality was identical with and without inhibitors. In severe hemophilia without HIV but with inhibitors, mortality from causes involving bleeding decreased during 1977-99 (P = 0.001) as did mortality involving intracranial hemorrhage (P = 0.007). CONCLUSIONS: These data provide estimates of the rate of inhibitor development in hemophilia A and hemophilia B, and they show that the rate of inhibitor development has varied over time, although the reasons for this remain unclear. They also show that in severe hemophilia the substantial increase in mortality previously associated with inhibitors is no longer present.
Subject(s)
Hemophilia A/immunology , Hemophilia B/immunology , Isoantibodies/blood , Adolescent , Child , Child, Preschool , Databases as Topic , Factor IX/immunology , Factor VIII/immunology , HIV Infections/mortality , Hemophilia A/epidemiology , Hemophilia A/mortality , Hemophilia B/epidemiology , Hemophilia B/mortality , Humans , Incidence , Longitudinal Studies , Male , Risk , Survival Rate , Time Factors , United KingdomABSTRACT
The development of inhibitory antibodies is a complication which arise in approximately 10% of patients with haemophilia A. The underlying genetic mutation is the single most important predisposing cause, although other risk factors have been identified. Periodic screening for inhibitors is a vital aspect of haemophilia care. The consequences of inhibitor development are very significant in terms of morbidity and cost. Several agents are now available for control of bleeding, but these are often very expensive. The most useful agents include recombinant activated factor VII, prothrombin complex concentrates and porcine factor VIII. It is possible to suppress antibody production with immune tolerance, which is successful in approximately 85% of cases and relapse is rare.
Subject(s)
Blood Coagulation Factor Inhibitors/immunology , Hemophilia A/immunology , Hemophilia A/therapy , Blood Coagulation Factor Inhibitors/blood , Blood Coagulation Factors/therapeutic use , Child , Child, Preschool , Factor VIII/therapeutic use , Factor VIIa/therapeutic use , Genetic Predisposition to Disease , Hemophilia A/blood , Hemophilia A/genetics , Humans , Immune Tolerance/drug effects , InfantABSTRACT
The amount and function of von Willebrand factor (VWF), measured against a panel of laboratory tests, is the normal basis for the diagnosis of von Willebrand's disease (VWD). The normal range for each test is usually obtained by assaying samples from a cross section of the local population or from a manufacturer's kit insert. While collecting normal controls for another study, population from Durban in South Africa, with its distinct ethnic mix of Africans, Indians and Caucasians were also studied. Previously, Indians from their subcontinent have not been looked at separately and compared with Africans and Caucasians. It is confirmed in a previous study (Miller, Dilley, Richardson, Craig, Evatt. (2001) American Journal of Hematology 67, 125) that African Americans had significantly higher VWF:Ag and FVIII levels when compared with Caucasians. In addition, it was found that there was a significant difference in VWF:Ag levels between Indians and Africans, and between Caucasians and Africans, whereas no significant difference between Indians and Caucasians. Africans, Indians and Caucasians with blood group O showed significantly lower VWF:Ag and FVIII than the other ABO blood groups. Normal ranges of VWF for different blood groups are well established and this information should be utilized while considering a diagnosis of VWD. It is proposed here that the influence of racial origin should also be considered in the clinical and laboratory evaluation of VWD.
Subject(s)
Ethnicity/genetics , Racial Groups/genetics , von Willebrand Diseases/ethnology , von Willebrand Factor/analysis , ABO Blood-Group System/analysis , ABO Blood-Group System/genetics , Africa/ethnology , Black People/genetics , Europe/ethnology , Female , Genetic Variation , Humans , India/ethnology , Male , Reference Values , South Africa , White People/genetics , von Willebrand Diseases/blood , von Willebrand Diseases/diagnosis , von Willebrand Diseases/genetics , von Willebrand Factor/geneticsABSTRACT
The World Federation of Haemophilia (WFH) Twinning Programme celebrates its tenth anniversary this year. Twinning is one of several international WFH programmes designed to improve haemophilia care at a global level. There are two types of twinning, and the haemophilia treatment centre twinning programme should be distinguished from the WFH haemophilia organization twinning involving national member organizations. The WFH Haemophilia Treatment Centre Twinning Programme helps emerging haemophilia treatment centres develop partnerships with well-established and experienced centres. Twinning can improve diagnosis and clinical care through coaching, training and transfer of expertise, ultimately leading to improved quality of life for patients. Twinning can also enhance the profile and recognition of treatment centres in emerging countries, which can be valuable in raising awareness among politicians and the media. Examples of activities include consultation on the management of specific cases, clinical and laboratory training, donation of equipment and publications as well as research projects. The centre twinning programme also benefits centres in developed countries by giving them the opportunity to gain exposure to clinical problems no longer encountered in their own countries, as well as experience of new cultures. Currently, a total of 23 treatment centres around the world are linked through the twinning programme and applications for new partnerships are welcome. Twinning links are not permanent, but are reviewed on an annual basis and typically remain in place for periods of 3-5 years. Limited financial support from WFH is available to twinned centres in the form of money for an initial assessment visit, as well as regular annual grants to established partners and the possibility of applying for additional funding to support specific projects. In addition, continuing support and advice are available from the WFH regional programme officers.
Subject(s)
Hemophilia A/therapy , Hemophilia B/therapy , International Agencies , International Cooperation , Developing Countries , HumansABSTRACT
Participants in an international conference on prophylactic therapy for severe haemophilia developed a consensus summary of the findings and conclusions of the conference. In the consensus, participants agreed upon revised definitions for primary and secondary prophylaxis and also made recommendations concerning the need for an international system of pharmacovigilance. Considerations on starting prophylaxis, monitoring outcomes, and individualizing treatment regimens were discussed. Several research questions were identified as needing further investigation, including when to start and when to stop prophylaxis, optimal dosing and dose interval, and methods for assessment of long-term treatment effects. Such studies should include carefully defined cohorts, validated orthopaedic and quality-of-life assessment instruments, and cost-benefit analyses.